Inhibition by parathyroid hormone of glycogen synthesis in the perfused rat liver  by Hems, D.A. et al.
Volume 58, number 1 FEBS LETTERS October 1975 
INHIBITION BY PARATHYROID HORMONE OF GLYCOGEN 
SYNTHESIS IN THE PERFUSED RAT LIVER 
D. A. HEMS, C. S. HARMON and P. D. WHITTON 
Department of Biochemistry, and Imperial College of Science and Technology, London, SW7 2AZ, UK 
Received 21 July 1975 
1. Introduction 2. Materials and methods 
Parathyroid hormone can exert effects on meta- 
bolic processes; thus it may stimulate renal gluconeo- 
genesis [l-3] or adipose tissue lipolysis [4-61. The 
renal content of cyclic adenosine 3’5’ monophosphate 
(cyclic AMP) is increased in response to parathyroid 
hormone, [ 1,7] . Hormones which act in the above 
fashion on kidney or fat, might be expected, by 
analogy with e.g. adrenalin and glucagon, to stimulate 
hepatic glycogen breakdown. Therefore this possibil- 
ity was tested in the perfused rat liver. Rather than 
following glucose output, glycogen metabolism was 
tested directly, to exclude effects on gluconeogenesis; 
thus net glycogen synthesis was measured, as previous- 
ly described [9,10]. This process exhibits greater 
sensitivity to another ‘catabolic’ hormone, viz. 
vasopressin, than does glycogen breakdown in livers 
from fed rats [lo] , which was another reason for 
selecting glycogen synthesis for study. 
The results presented here demonstrate that 
parathyroid hormone can inhibit hepatic net glycogen 
synthesis. During the progress of these experiments, 
reports appeared of stimulation by parathyroid hormone 
of glucose output in hepatocytes [ 1 l] and of cyclic 
AMP formation by the liver [ 11,121. The present 
work complements these studies, in documenting the 
hormone concentration-dependence of the action on 
hepatic glycogen metabolism, in the perfused liver, 
i.e. in a preparation where hormone responses may be 
reasonably presumed to correspond closely to events 
in vivo . 
Male Sprague-Dawley rats (200 g) were starved 
for 48 h from 10.00 h. Net glycogen synthesis was 
measured by a sequential-biopsy procedure in livers 
perfused with 50 ml saline containing albumin, red 
cells, glucose and gluconeogenic precursors, as de- 
scribed previously [9,10]. 
Parathyroid hormone (Lot 74/286) was very 
kindly provided by Dr J. A. Parsons (National Institute 
of Medical Research, Mill Hill, London, NW7, UK), 
and Dr J. R. L. O’Riordan (Middlesex Hospital, 
London W.l., UK). This material contained, per 
ampoule, 170 gg highly purified hormone, and 259 mg 
mannitol. For use, it was dissolved in about 1 ml 1% 
(w/v) bovine serum albumin (‘Crystalline’, Sigma Ltd) 
which had been heated at 56°C (pH 7.0) for 2 h. 
When the entire ampoule of hormone was not used 
during a day’s perfusions, the solution (pH 4.0) was 
rapidly frozen (using liquid nitrogen) in small aliquots, 
being used subsequently after only one thaw. 
3. Results 
Parathyroid hormone caused a gradually increasing 
inhibition of net glycogen synthesis, over the concen- 
tration range 0.6-2.0 pg/ml (about 6 X lo- * M- 
2 X 1 OF7 M) as shown in tig.l. In control perfusions 
with an appropriate amount of mannitol and albumin 
dihrent (corresponding to maximum hormone addi- 
tions), no change in glycogen synthesis occurred 
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or 4. Discussion 
0.9 1.8 
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Fig. 1. Livers from 48-h starved rats were perfused as described 
in the text, and elsewhere, [9,10]. Parathyroid hormone was 
added as a single dose after 15 min. and glycogen synthesis 
(expressed per g of wet liver) was measured by a serial biopsy 
technique, involving liver samples removed after 20 and 50 
min. The perfusate volume was 50 ml, except in two of the 
three perfusions at 630 ng/ml, when parathyroid hormone 
was added in a single dose to 150 ml perfusate. In two control 
perfusions (without parathyroid hormone: A) mannitol was 
added, since this carrier was present in the hormone prepara- 
tion (see text). Results are means t S.E.M. (bars) of three 
perfusions, except for those without hormone (12 perfusions). 
(r&.1). The inhibitory effect of parathyroid hormone 
(fig.1) was confirmed in two further perfusions in 
which two doses of hormone were added, after 15 and 
2.5 min perfusion, producing concentrations (each 
time) of 0.8 and 1.3 pg/ml. respectively; the rates of 
glycogen deposition were 0.08 pmol and 0.00 pmol 
of glycogen-glucose/min/g, respectively. 
An inhibition of net glycogen synthesis should 
also be manifest as a stimulation of glycogen break- 
down in livers from fed rats. We sought such an effect 
in many experiments, but no consistent action was 
discerned, (results not shown), presumably because 
any effects were too slow and slight to be detectable 
over basal glucose output, despite the slow rate of 
glucose release before hormone addition (as in com- 
parable experiments with vasopressin: ref. [IO] ). This 
could also reflect a relative insensitivity to hormone 
in fed rat livers, as in the case of vasopressin [lo]. 
The concentration-response curve for the action 
of parathyroid hormone on hepatic glycogen metabo- 
lism corresponds to those reported for its actions on 
hepatic cyclic AMP, [ 11 ,121, on renal gluconeo- 
genesis [ 1,3], and on adipose tissue triglyceride [4,6]. 
Also, stimulation of glucose output in hepatocytes 
[ 1 l] exhibits the same concentration-dependence; 
thus in the particular case of parathyroid hormone, 
there appears to be no alteration in receptors during 
hepatocyte preparation, and no involvement of the 
intact cyto-architecture in hormone action (these 
being possible explanations of the decrease in sensi- 
tivity to glucagon or adrenalin, in hepatocytes com- 
pared to perfusions: ref. [ 131). 
The glycogenolytic action of parathyroid hormone, 
reported here for the intact liver, raises questions 
about the metabolic status of patients with para- 
thyroid disorders. Mild alterations in glucose tolerance 
[ 141 or insulin status [ 14,151 can occur in hyper- 
parathyroidism, as can increased plasma parathyroid 
hormone levels in diabetes [ 161 ; however, these 
changes do not appear to be very great. Also the con- 
centration-dependence of the hepatic action, and 
indeed of all the metabolic actions of parathyroid 
hormone yet reported, suggest hat these effects may 
not have great significance in the intact animal, where 
circulating hormone levels apparently do not exceed 
about 10 ng/ml [17] and could be much less [l&19]. 
Yet it remains possible that these effects have counter- 
parts with functional importance, e.g. on different 
processes (in the same organ), and perhaps exerted 
by a hormone fragment [20] or requiring unknown 
cofactors. 
It is possible that the present experiments have 
produced an under-estimate of the sensitivity of the 
liver to the hormone, as only one dose was added 
during perfusion. This is however, unlikely on 
general grounds, since glycogen synthesis was mea- 
sured during only 30 min of perfusion, and also for 
the following reasons: (i) results agree with those in 
other preparations, (ii) two experiments with larger 
perfusion volumes (which would minimise hormone 
destruction) did not reveal inhibition of synthesis at 
a concentration of about 0.6 pg/ml. (iii) the destruc- 
tion of parathyroid hormone in the perfused liver 
does not appear to be rapid [20]. However, it is 
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possible that rat parathyroid hormone might have 
more potent effects on rat liver, than bovine hormone, 
or that sensitivity to hormone might be increased in 
different perfusion conditions. 
There are clues about where the significance of a 
hepatic action of parathyroid hormone may lie. Thus 
actions on liver mitochondria [21] and blood flow 
[22] have been observed. Any such putative effect 
does not appear to involve rapid fluxes of calcium or 
phosphate in response to native parathyroid hormone, 
as no changes in these parameters, in effluent perfusate, 
were observed in the present experiments (results not 
shown). However, liver may have a role in calcium 
movements [23 --251 e.g. in the longer-term. Broader 
aspects of a hepatic effect of parathyroid hormone 
could involve inter-relations with calcitonin [26] , 
liver regeneration [27,28], haemorrhagic shock [29], 
or acidosis [30]. It seems reasonable to speculate [ 121 
that parathyroid hormone might influence hepatic 
vitamin D metabolism. 
Clearly, there are further aspects of the role of the 
parathyroid gland in metabolic events, including 
possible hepatic effects, which require clarification. 
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